Investment analysts at Stifel Nicolaus initiated coverage on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage set a “hold” rating and a $27.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential downside of 2.28% from the stock’s previous close.

Several other research analysts have also recently commented on ALLO. Zacks Investment Research cut shares of Allogene Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 3rd. William Blair restated a “buy” rating on shares of Allogene Therapeutics in a report on Monday, April 15th. Oppenheimer began coverage on shares of Allogene Therapeutics in a report on Friday, May 3rd. They set an “outperform” rating and a $45.00 target price for the company. Raymond James began coverage on shares of Allogene Therapeutics in a report on Thursday, March 14th. They set an “outperform” rating and a $40.00 target price for the company. Finally, Cowen restated a “buy” rating on shares of Allogene Therapeutics in a report on Friday, March 8th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $36.63.

Allogene Therapeutics stock opened at $27.63 on Wednesday. The company has a market capitalization of $3.54 billion and a PE ratio of -4.20. Allogene Therapeutics has a twelve month low of $21.67 and a twelve month high of $35.55.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Tuesday, May 7th. The company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Sell-side analysts expect that Allogene Therapeutics will post -1.92 EPS for the current fiscal year.

In other Allogene Therapeutics news, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of the stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $29.38, for a total value of $56,373,021.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of hedge funds have recently made changes to their positions in the business. Barclays PLC bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $27,000. Legal & General Group Plc bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $89,000. NumerixS Investment Technologies Inc bought a new position in shares of Allogene Therapeutics in the first quarter valued at about $136,000. Partner Investment Management L.P. bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $135,000. Finally, Citigroup Inc. bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at about $152,000. Hedge funds and other institutional investors own 53.39% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Featured Story: Forex

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.